Anzeige
Mehr »
Freitag, 22.05.2026 - Börsentäglich über 12.000 News
Nach dem Tungsten-Schock: Startet hier jetzt die nächste große US-Critical-Minerals-Story?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CSR9 | ISIN: US00032Q1040 | Ticker-Symbol: 3350
Tradegate
21.05.26 | 12:39
3,700 Euro
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
WHITEHAWK THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
WHITEHAWK THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
3,6803,72007:20
3,6403,80006:56

Aktuelle News zur WHITEHAWK THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoWhitehawk Therapeutics, Inc. - 8-K, Current Report1
13.05.Whitehawk Therapeutics secures $87.5M PIPE financing1
13.05.Whitehawk Therapeutics raises $87.5m in private placement7
11.05.Whitehawk Therapeutics stock rating reaffirmed at Citizens on ADC progress1
07.05.Whitehawk Therapeutics, Inc. - 10-Q, Quarterly Report-
07.05.Whitehawk Therapeutics GAAP EPS of -$0.324
07.05.Whitehawk Therapeutics, Inc. - 8-K, Current Report-
WHITEHAWK THERAPEUTICS Aktie jetzt für 0€ handeln
07.05.Whitehawk Therapeutics, Inc.: Whitehawk Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights383Phase 1 trials for HWK-007 and HWK-016 are ongoing; an IND submission for HWK-206 is on track for mid-2026 Cash, cash equivalents and short-term investments balance...
► Artikel lesen
20.04.Whitehawk Therapeutics presents preclinical data on three ADC candidates at AACR1
16.04.Whitehawk Therapeutics jumps as Citizens issues Outperform rating ahead of trial data1
10.04.Whitehawk Therapeutics untermauert mit neuen Daten Potenzial von MUC16 als ADC-Ziel bei Eierstockkrebs1
10.04.Whitehawk Therapeutics presents data on MUC16 target for ovarian cancer ADC1
10.04.Whitehawk Therapeutics, Inc.: Whitehawk Therapeutics Presents Real-World Analysis Confirming MUC16 as a Highly Expressed, Clinically Relevant Target for Gynecologic Cancers at SGO 2026192MUC16 is the highest-expressing ADC target in ovarian cancer, at least two-fold higher than other emerging targets MUC16 is highly and stably expressed in the most...
► Artikel lesen
12.03.Whitehawk Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans1
12.03.Whitehawk Therapeutics, Inc. - 10-K, Annual Report1
12.03.Whitehawk Therapeutics GAAP EPS of -$0.341
12.03.Whitehawk Therapeutics, Inc. - 8-K, Current Report-
22.12.25Jones Trading startet Coverage für Whitehawk Therapeutics mit Kaufempfehlung6
22.12.25Jones Trading initiates coverage on Whitehawk Therapeutics stock with Buy rating2
01.12.25Whitehawk Therapeutics, Inc.: Whitehawk Therapeutics Appoints Margaret Dugan, MD, as Chief Medical Officer255Dr. Dugan brings extensive clinical development leadership to Whitehawk as ADC programs near the clinic MORRISTOWN, N.J., Dec. 1, 2025 /PRNewswire/ -- Whitehawk...
► Artikel lesen
Weiter >>
22 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1